Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

Ansar A. Pathan, Clare R. Sander, Helen A. Fletcher et al. · 2007

Read Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials by Ansar A. Pathan, Clare R. Sander, Helen A. Fletcher et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001052.txt.

Description

Ansar Pathan, Clare Sander, Helen Fletcher and colleagues tested boosting the TB vaccine with a modified virus, in PLOS ONE in 2007. BCG is the standing tuberculosis vaccine, and its protection fades. The booster candidate, MVA85A, is a modified vaccinia virus carrying a TB antigen called 85A.

The team investigated the safety and immune effects of giving the boost shortly after BCG. They compared results with BCG alone and with an earlier trial using a longer interval. Timing can make or break a booster, since the first vaccine's response is still rising. Their comparison helps set the schedule for larger efficacy trials.

Catalog record

CREATORAnsar A. Pathan, Clare R. Sander, Helen A. Fletcher et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001052

Browse the full library · About the Tower of Babel